Oncogenic activity of RAS is not the result of overactive RAS signaling but rather the disruption of normal negative feedback mechanisms operated by the oncogenic GTPase
Other examples of this process include loss-of-function mutations in phosphatase and tensin homolog (PTEN), which amplify phosphatidylinositol 3-kinase (PI3K) signaling